Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	**4DMedical Limited**
ABN	**31 161 684 831**

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Robert Alan Figlin
Date of last notice	4 March 2026

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Robert Figlin atf Robert Figlin Revocable Trust: • Beneficiary of Robert Figlin Revocable Trust
Date of change	27 November 2026
No. of securities held prior to change Robert Figlin atf Robert Figlin Revocable Trust	882,840 Ordinary Shares
Class	Performance rights
Number acquired	11,406 Restricted Stock Units (performance rights)
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Restricted Stock Units (performance rights) issued as a component of director's remuneration (valued at $45,500 based on the 30-day-VWAP of $3.99 as at 1 July 2026).

+ See chapter 19 for defined terms.

No. of securities held after change	**Direct** 11,406 Restricted Stock Units (performance rights) **Indirect** *Robert Figlin atf Robert Figlin Revocable Trust* 882,840 ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Restricted Stock Units as approved at the Annual General Meeting on 28 October 2026.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

227Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	**4DMedical Limited**
ABN	**31 161 684 831**

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	John Livingston
Date of last notice	26 June 2026

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Ordinary shares in which the beneficial interest is held by John Livingston Pty Ltd, an entity controlled by John Livingston (registered holder: Colonial First State Inv Ltd <4916557 JOHN A/C>); and Ordinary shares in which the beneficial interest is held by JKEL Super Pty Ltd, an entity in which John Livingston has a voting power above 20% and thus is deemed by Section 608(3) of the Corporations Act 2001 to have the same relevant interest (registered holder: Colonial First State Inv Ltd <4916510 JKEL A/C>).
Date of change	27 November 2026

+ See chapter 19 for defined terms.

No. of securities held prior to change	**Direct** 60,147 fully paid ordinary shares **Indirect** *Colonial First State Inv Ltd <4916557 JOHN A/C>) (beneficial holder John Livingston Pty Ltd)* 671,656 fully paid ordinary shares *Colonial First State Inv Ltd <4916510 JKEL A/C (beneficial holder: JKEL Super Pty Ltd* 1,501,344 ordinary fully paid shares
Class	Unquoted Options with a nil exercise price and expiry date of 30 June 2031
Number acquired	11,406 Unquoted Options
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Unquoted options issued as a component of director's remuneration (valued at $45,500 based on the 30-day-VWAP of $3.99 as at 1 July 2026).
No. of securities held after change	**Direct** 60,147 fully paid ordinary shares **Indirect** *Colonial First State Inv Ltd <4916557 JOHN A/C>) (beneficial holder John Livingston Pty Ltd)* 671,656 fully paid ordinary shares 11,406 Unquoted Options with a nil exercise price and expiry date of 30 June 2031 *Colonial First State Inv Ltd <4916510 JKEL A/C (beneficial holder: JKEL Super Pty Ltd* 1,501,344 ordinary fully paid shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of options as approved at the Annual General Meeting on 28 October 2026.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A

+ See chapter 19 for defined terms.

Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	**4DMedical Limited**
ABN	**31 161 684 831**

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Geraldine Bernadette McGinty
Date of last notice	4 March 2026

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	27 November 2026
No. of securities held prior to change	391,251 ordinary shares
Class	Performance rights
Number acquired	11,406 Restricted Stock Units (performance rights)
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Restricted Stock Units (performance rights) issued as a component of director's remuneration (valued at $45,500 based on the 30-day-VWAP of $3.99 as at 1 July 2026).

+ See chapter 19 for defined terms.

No. of securities held after change	391,251 ordinary shares 11,406 Restricted Stock Units (performance rights)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Restricted Stock Units as approved at the Annual General Meeting on 28 October 2026.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.